131 related articles for article (PubMed ID: 28332573)
1. Discovery of multi-target receptor tyrosine kinase inhibitors as novel anti-angiogenesis agents.
Wang J; Zhang L; Pan X; Dai B; Sun Y; Li C; Zhang J
Sci Rep; 2017 Mar; 7():45145. PubMed ID: 28332573
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors.
Sun Y; Shan Y; Li C; Si R; Pan X; Wang B; Zhang J
Eur J Med Chem; 2017 Dec; 141():373-385. PubMed ID: 29032031
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel anti-angiogenesis agents. Part 6: Multi-targeted RTK inhibitors.
Zhang L; Shan Y; Li C; Sun Y; Su P; Wang J; Li L; Pan X; Zhang J
Eur J Med Chem; 2017 Feb; 127():275-285. PubMed ID: 28068599
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4.
Li C; Shan Y; Sun Y; Si R; Liang L; Pan X; Wang B; Zhang J
Eur J Med Chem; 2017 Dec; 141():506-518. PubMed ID: 29102175
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel anti-angiogenesis agents. Part 9: Multiplex inhibitors suppressing compensatory activations of RTKs.
Shan Y; Si R; Wang J; Zhang Q; Zhou H; Song J; Zhang J; Chen Q
Eur J Med Chem; 2019 Feb; 164():440-447. PubMed ID: 30616052
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel anti-angiogenesis agents. Part 10: Multi-target inhibitors of VEGFR-2, Tie-2 and EphB4 incorporated with 1,2,3-triazol.
Pan X; Liang L; Si R; Wang J; Zhang Q; Zhou H; Zhang L; Zhang J
Eur J Med Chem; 2019 Feb; 163():1-9. PubMed ID: 30503935
[TBL] [Abstract][Full Text] [Related]
7. Discovery and evaluation of triple inhibitors of VEGFR-2, TIE-2 and EphB4 as anti-angiogenic and anti-cancer agents.
Zhang L; Shan Y; Ji X; Zhu M; Li C; Sun Y; Si R; Pan X; Wang J; Ma W; Dai B; Wang B; Zhang J
Oncotarget; 2017 Dec; 8(62):104745-104760. PubMed ID: 29285210
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel VEGFR-2 inhibitors. Part 5: Exploration of diverse hinge-binding fragments via core-refining approach.
Shan Y; Gao H; Shao X; Wang J; Pan X; Zhang J
Eur J Med Chem; 2015 Oct; 103():80-90. PubMed ID: 26342134
[TBL] [Abstract][Full Text] [Related]
9. Discovery of biphenyl-aryl ureas as novel VEGFR-2 inhibitors. Part 4: exploration of diverse hinge-binding fragments.
Su P; Wang J; Shi Y; Pan X; Shao R; Zhang J
Bioorg Med Chem; 2015 Jul; 23(13):3228-36. PubMed ID: 25982075
[TBL] [Abstract][Full Text] [Related]
10. New strategies in achieving antiangiogenic effect: Multiplex inhibitors suppressing compensatory activations of RTKs.
Shan Y; Wang B; Zhang J
Med Res Rev; 2018 Sep; 38(5):1674-1705. PubMed ID: 29878411
[TBL] [Abstract][Full Text] [Related]
11. Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4.
Mitchell SA; Danca MD; Blomgren PA; Darrow JW; Currie KS; Kropf JE; Lee SH; Gallion SL; Xiong JM; Pippin DA; DeSimone RW; Brittelli DR; Eustice DC; Bourret A; Hill-Drzewi M; Maciejewski PM; Elkin LL
Bioorg Med Chem Lett; 2009 Dec; 19(24):6991-5. PubMed ID: 19879134
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase.
Shi ZH; Liu FT; Tian HZ; Zhang YM; Li NG; Lu T
Bioorg Med Chem; 2018 Sep; 26(16):4735-4744. PubMed ID: 30121211
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 6-Arylurea-2-arylbenzoxazole and 6-Arylurea-2-arylbenzimidazole Derivatives as Angiogenesis Inhibitors: Design, Synthesis and in vitro Biological Evaluation.
Zi M; Liu F; Wu D; Li K; Zhang D; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
ChemMedChem; 2019 Jul; 14(13):1291-1302. PubMed ID: 31131561
[TBL] [Abstract][Full Text] [Related]
14. Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
Wang X; Chen Z; Tong L; Tan S; Zhou W; Peng T; Han K; Ding J; Xie H; Xu Y
Eur J Med Chem; 2013 Jul; 65():477-86. PubMed ID: 23770449
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel VEGFR-2 inhibitors. Part II: biphenyl urea incorporated with salicylaldoxime.
Gao H; Su P; Shi Y; Shen X; Zhang Y; Dong J; Zhang J
Eur J Med Chem; 2015 Jan; 90():232-40. PubMed ID: 25461323
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors.
Machado VA; Peixoto D; Costa R; Froufe HJ; Calhelha RC; Abreu RM; Ferreira IC; Soares R; Queiroz MJ
Bioorg Med Chem; 2015 Oct; 23(19):6497-509. PubMed ID: 26344591
[TBL] [Abstract][Full Text] [Related]
17. The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents.
Zhang X; Raghavan S; Ihnat M; Hamel E; Zammiello C; Bastian A; Mooberry SL; Gangjee A
Bioorg Med Chem; 2015 May; 23(10):2408-23. PubMed ID: 25882519
[TBL] [Abstract][Full Text] [Related]
18. The anti-angiogenic and anti-tumor activity of synthetic phenylpropenone derivatives is mediated through the inhibition of receptor tyrosine kinases.
Lee JS; Kang Y; Kim JT; Thapa D; Lee ES; Kim JA
Eur J Pharmacol; 2012 Feb; 677(1-3):22-30. PubMed ID: 22200628
[TBL] [Abstract][Full Text] [Related]
19. Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes.
Zhang J; Zhang L; Wang Y; Zhao G
Cancer Chemother Pharmacol; 2016 May; 77(5):905-26. PubMed ID: 26781310
[TBL] [Abstract][Full Text] [Related]
20. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]